News & Blogs

C2S Releases New Video Advertisement Asking: Who is AARP Really Watching Out For?

Phil Kerpen: Letter: The truth behind AARP’s push for price controls

Terry Wilcox’s op-ed highlighting AARP’s apparent conflict of interest with insurance giants brings much-needed attention to the real reason behind the AARP’s support for price controls in President Joe Biden’s spending bill. While AARP maintains that it merely supports Speaker of the House Nancy Pelosi’s Medicare “negotiation” plan because it wants to lower seniors’ drug costs, that simply isn’t the case. In reality, the organization’s true motive is maintaining its billion-dollar relationship with UnitedHealthcare. UHC…

Terry Wilcox: AARP has a conflict of interest when it comes to drug pricing legislation. That could hurt the seniors it protects.

AARP is the nation’s biggest and most influential advocacy group for seniors. It has about 38 million members — more than 11% of the U.S. population. From lobbying for better conditions in nursing homes to getting travel discounts for members, the organization has done much to help retired people over the years. When it comes to one of AARP’s signature products, though, it may not always be putting its members first. The problem is that…

Jack Rowing: Profitable Healthcare Activism

Politics is filled with hot-button issues. Polarizing topics are routinely brought up on twitter, in congressional meetings, and during rose garden speeches. Abortion, guns, and policing are all on the table and docket. This is in large part due to activists who make a living on keeping issues in the spotlight to enact change. It has become a highly lucrative field. Recent news reports of BLM activists making millions of dollars through fraud, and buying…

AARP Overcharges Seniors to Raise Its Bottom Line

In a recent exposé, the Daily Caller News Foundation details how “AARP Rakes in Record Profits Selling Brand Royalties While Overcharging Members.” While the organization bills itself as a scrappy senior advocacy group, its recent financial disclosures—as well as its own admission in court—cast serious doubt on whether it acts “with the interest of its members in mind.” The Daily Caller took a deep dive into AARP’s money tree and the resulting conflict of interest.…

Jon Decker: Why Build Back Better’s prescription price controls are a bad idea

Joe Biden’s “Build Back Better” nonsense is getting a boost from an extremely powerful and well-funded lobbying force — AARP — and it’s time for us to call them out on it. The so-called “seniors advocacy organization” has been pushing hard for the passage of Biden’s massive, inflation-inducing spending bill. Why? Because the House version of the bill would have the federal government set the price of prescription drugs under the guise of “negotiation.” If…

On Build Back Better and Gasoline: Why Price Controls Are Always A Bad Idea

Biden’s “Build Back Better” nonsense is getting a boost from an extremely powerful and well-funded lobbying force—the AARP—and it’s time for us to call them out on it. The so-called “seniors advocacy organization” has been pushing hard for the passage of Biden’s massive, inflation-inducing spending bill. Why? Because the House version of the bill would have the federal government set the price of prescription drugs under the guise of “negotiation.” If the bill were enacted,…

Newt Gingrich: Democrats say they are the party of science but their drug price plans tell a different story

The Democrats like to present themselves as the party of science, but two recent announcements show just how ignorant they are about how science moves from the lab into our medicine cabinet. The first announcement was results from Pfizer’s clinical trial of its new anti-viral treatment for COVID-19. The treatment reduced hospital admissions in high-risk individuals by a stunning 90 percent compared to those receiving a placebo. Even more remarkably, not a single person receiving…